ArticleBMC oral health2026
Vortioxetine mitigates methotrexate-induced oral mucosa injury via sirtuin 1 pathway and intrinsic apoptosis signaling.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate (MTX) commonly causes oral mucositis by inducing epithelial cytotoxicity and inflammation, leading to functional impairment and treatment limitations. Therefore, agents that can protect oral tissues without reducing MTX efficacy are needed. Vortioxetine (VOR), with its reported anti-inflammatory and antioxidant actions, may offer such therapeutic potential.
methodsThirty-two adults female Wistar rats were divided into four groups: Control, MTX, VOR and MTX + VOR (n = 8 each), weighed 300–350 g and were 10–12 weeks old. VOR (10 mg/kg/day, intraperitoneally [i.p.]) was administered continuously for five days and a single dose of MTX (20 mg/kg, i.p.) was injected 30 min after the first VOR dose on day 1. On day 5, maxillary gingival and tongue tissues were carefully harvested for comprehensive analyses. Histopathological evaluation was performed to assess structural alterations, while immunohistochemical staining was conducted to determine the expression levels of caspase-3 (Casp3) and tumor necrosis factor-alpha (Tnfa). In addition, molecular analyses were carried out to quantify the gene expression profiles of sirtuin 1 (Sirt1), nuclear factor erythroid 2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Ppargc1a), B-cell lymphoma 2 (Bcl2), and Bcl2-associated X protein (Bax), thereby enabling a comprehensive evaluation of apoptotic, inflammatory, and oxidative stress–related pathways.
resultsMTX treatment caused increased Tnfa and Casp3 immunoexpressing, leading to severe epithelial degeneration, hyperemia and inflammatory cell infiltration in the oral mucosa. Gene expression analysis supported that there was a significant upregulation of proapoptotic (Bax, Casp3) and inflammatory markers (Tnfa) whereas a downregulation of mitochondrial regulators (Sirt1, Nrf2, Ppargc1a, Bcl2). Co-treatment with VOR markedly reversed these changes.
conclusionVOR significantly ameliorated the damage caused by MTX to the oral mucosa by interfering with the Sirt1/ Nrf2/ Ppargc1a antioxidant axis and suppressing the Bax/Bcl2/ Casp3 apoptotic pathway. These results indicate that VOR can be used as a valuable therapeutic agent that can be combined with chemotherapy to alleviate side effects in the oral mucosa by restoring redox homeostasis, mitochondrial integrity and cellular survival signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.